Supernus and Indivior to Merge, Forming CNS Powerhouse
SUPN sits 35% above its 52-week low of $32.83.
Summary
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging to create a diversified CNS biopharmaceutical leader with significant scale, with the combined company to be named Supernus. The deal combines Supernus's growing CNS portfolio—recently boosted by a 39% Q1 revenue jump and a $33.4M milestone payment—with Indivior's established addiction treatment franchise, resulting in a diversified portfolio of CNS medicines totaling about $2.2 billion in combined annual revenue. Indivior holders will receive a one-time special cash dividend of $1 billion, and the companies have secured a $650 million debt commitment through a loan facility. The merger follows a period of strong operational momentum for Supernus, including shareholder approval of an equity incentive plan increase in June, and Q2 revenue rose on prescription volume. Q2 results are due August 4, which may provide additional context on the standalone trajectory ahead of the deal's close.
At the time of this announcement, SUPN was trading at $44.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $32.83 to $59.68. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.